European stocks close lower on renewed trade worries; Sanofi buys U.S. rival

European stocks close lower on renewed trade worries; Sanofi buys U.S. rival#European #stocks #close #renewed #trade…

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in…

Sanofi to buy Blueprint Medicines for $9.1 bln

Sanofi to buy Blueprint Medicines for $9.1 bln#Sanofi #buy #Blueprint #Medicines #bln

Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment

Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment #Sanofi #Finding #Wake #Itepekimab039s #Disappointment

Itepekimab Failure A Setback For Sanofi And Regeneron

Itepekimab Failure A Setback For Sanofi And Regeneron #Itepekimab #Failure #Setback #Sanofi #Regeneron

Sanofi plans share buybacks, signals more deals post Opella sale 

Sanofi plans share buybacks, signals more deals post Opella sale #Sanofi #plans #share #buybacks #signals #deals #post…

Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul…

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China By Investing.com

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Cytokinetics (NASDAQ:), Incorporated  (Nasdaq: CYTK) today…